The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio (elranatamab), a bispecific antibody targeting BCMA and CD3, is on track for priority review as a potential treatment for triple-class exposed (TCE) relapsed or refractory multiple myeloma (r/r MM). This development signifies a significant step forward in the global effort to provide advanced therapies for patients battling this form of cancer.
Elranatamab, which has garnered attention for its innovative approach to cancer treatment, was fast-tracked for marketing approval in the US in August 2023. It is designed to treat adult patients with r/r MM who have undergone at least four prior lines of therapy, demonstrating the drug’s potential to address unmet needs in the market.
The priority review status in China reflects the CDE’s commitment to expediting the availability of life-saving medications, particularly for those with limited treatment options. As Pfizer’s Elrexfio moves through the regulatory process, it highlights the company’s dedication to improving outcomes for patients with multiple myeloma worldwide.- Flcube.com
